- Social Responsibility
- Social Responsibility
- Our Giving
- Corporate Social Responsibility
- Be The First Tobacco-Free Generation
- Community Stories
- Thought Leadership
- Search Jobs
- Investor Story
- Results Center
- 2017 In Review
- Financial Information
- SEC Filings
- Events & Presentations
- Stock Information
- Corporate Governance
- Investor Resources
CVS Caremark Research Finds Eliminating Medication Copays Post-Heart Attack Can Improve Health Outcomes for Non-White Patients
Monday, May 5, 2014
WOONSOCKET, R.I., May 5, 2014 /PRNewswire/ -- A new study by researchers at CVS Caremark (NYSE: CVS), Aetna and Brigham and Women's Hospital published today in the May issue of Health Affairs, finds that eliminating copays for preventive medications prescribed for post-heart attack patients, can significantly improve medication adherence and health outcomes for non-white patients. The analysis suggests that this approach may be an effective strategy for reducing commonly recognized disparities in cardiovascular care related to patient ethnicity and race.
Racial and ethnic disparities in cardiovascular care have been widely documented in the peer-reviewed literature and persist despite overall improvements in cardiovascular mortality and risk factor control. In fact, research by CVS Caremark (NYSE: CVS) and Brigham and Women's Hospital published last year in The American Heart Journal, found that non-white patients had 50 percent greater odds of medication non-adherence to statin medications compared to white patients.
"A series of studies have demonstrated that a Value Based Insurance Design (VBID) approach that reduces or eliminates medication copays is a cost-effective strategy for increasing adherence and improving cardiovascular outcomes," said Niteesh K. Choudhry, MD, PhD, associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, associate professor, Harvard Medical School and the lead author of the study. "This new analysis demonstrates that VBID can also reduce disparities in cardiovascular care and health outcomes related to a patient's race and ethnicity."
The Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial conducted by Brigham and Women's Hospital, Harvard Medical School and Aetna (full results of which were previously published in the New England Journal of Medicine in 2011) originally compared full (i.e., no copayments, coinsurance or deductibles) with usual drug insurance coverage for all statin, beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) prescribed after a heart attack. In this new, secondary analysis, the researchers reviewed the data to see whether providing full coverage for post-MI medications had differential effects based on race and ethnicity. More than 2,300 individuals were included in the analysis of which 22.2 percent self-identified as being of non-white race/ethnicity.
The study found that:
- For all patients, full coverage significantly improved medication adherence.
- Providing full drug coverage significantly reduced rates of a post-MI major vascular event or revascularization among patients who self-identified as being non-white, but had no impact on clinical events for individuals of white race or ethnicity.
- Providing full drug coverage reduced total health care spending by 70 percent among patients who self-identified as being non-white.
"There have been a lot of studies demonstrating that disparities in care exist. This study shows us a straightforward way to reduce those disparities and improve health outcomes. We think this is an important contribution," said William H. Shrank, MD, MSHS, senior vice president and Chief Scientific Officer of CVS Caremark, and a study co-author. "We should note that the value based insurance design approach of eliminating copayments for maintenance medications after a heart attack is actually a relatively simple, low-risk change that should be considered for broader usage."
CVS Caremark's VBID program offering is aimed at removing the barrier of cost to help improve the medication adherence of members. There are currently more than 100 clients enrolled in the program that targets seven chronic conditions. The program is able to provide an increase of 4-9 percent in adherence (as measured by medication possession ratio) and more than 10 percent improvement in moving members with sub-optimal adherence to optimal adherence in certain cardiovascular diseases.
This analysis of medication adherence and the impact on racial and ethnic disparities was supported by an unrestricted research grant from Aetna to Brigham and Women's Hospital. CVS Caremark has been supporting a multi-year research collaboration with Brigham and Women's Hospital to better understand patient behavior, particularly around medication adherence. Annual excess health care costs due to medication non-adherence in the U.S. have been estimated to be as much as $290 billion.
About CVS Caremark
CVS Caremarkis dedicated to helping people on their path to better health as the largest integrated pharmacy company inthe United States. Through the company's more than 7,600 CVS/pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 800 MinuteClinic locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breadth of capabilities,CVS Caremarkcontinually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about howCVS Caremarkis reinventing pharmacy for better health at info.cvscaremark.com.
SOURCE CVS Caremark